Welcome to Critical MassLaw.com’s weekly briefing for class action and mass tort attorneys. This week, it’s all about settlements: What does Purdue’s $270 million settlement mean for the rest of the opioid litigation? Find out which cases are excluded from the Xarelto settlement. And a new report finds that the value of securities class action settlements surged in 2018.

Send your feedback to [email protected], or find me on Twitter: @abronstadlaw.

What’s Next for Opioid Cases After Purdue Pharma’s Settlement With Oklahoma?